PBH vs. RARE, AXSM, BHVN, BHC, XENE, FOLD, IDYA, CBAY, ARWR, and HCM
Should you be buying Prestige Consumer Healthcare stock or one of its competitors? The main competitors of Prestige Consumer Healthcare include Ultragenyx Pharmaceutical (RARE), Axsome Therapeutics (AXSM), Biohaven (BHVN), Bausch Health Companies (BHC), Xenon Pharmaceuticals (XENE), Amicus Therapeutics (FOLD), IDEAYA Biosciences (IDYA), CymaBay Therapeutics (CBAY), Arrowhead Pharmaceuticals (ARWR), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical preparations" industry.
Ultragenyx Pharmaceutical (NASDAQ:RARE) and Prestige Consumer Healthcare (NYSE:PBH) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, community ranking, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.
Ultragenyx Pharmaceutical has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500. Comparatively, Prestige Consumer Healthcare has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500.
Ultragenyx Pharmaceutical received 321 more outperform votes than Prestige Consumer Healthcare when rated by MarketBeat users. Likewise, 77.14% of users gave Ultragenyx Pharmaceutical an outperform vote while only 70.67% of users gave Prestige Consumer Healthcare an outperform vote.
In the previous week, Ultragenyx Pharmaceutical had 4 more articles in the media than Prestige Consumer Healthcare. MarketBeat recorded 12 mentions for Ultragenyx Pharmaceutical and 8 mentions for Prestige Consumer Healthcare. Ultragenyx Pharmaceutical's average media sentiment score of 0.84 beat Prestige Consumer Healthcare's score of 0.41 indicating that Prestige Consumer Healthcare is being referred to more favorably in the news media.
Ultragenyx Pharmaceutical currently has a consensus price target of $88.08, suggesting a potential upside of 99.09%. Prestige Consumer Healthcare has a consensus price target of $110.00, suggesting a potential upside of 56.09%. Given Prestige Consumer Healthcare's stronger consensus rating and higher possible upside, research analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Prestige Consumer Healthcare.
97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. Comparatively, 100.0% of Prestige Consumer Healthcare shares are owned by institutional investors. 6.8% of Ultragenyx Pharmaceutical shares are owned by company insiders. Comparatively, 1.6% of Prestige Consumer Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Prestige Consumer Healthcare has a net margin of -7.11% compared to Prestige Consumer Healthcare's net margin of -139.70%. Ultragenyx Pharmaceutical's return on equity of 14.09% beat Prestige Consumer Healthcare's return on equity.
Prestige Consumer Healthcare has higher revenue and earnings than Ultragenyx Pharmaceutical. Prestige Consumer Healthcare is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Summary
Ultragenyx Pharmaceutical beats Prestige Consumer Healthcare on 10 of the 18 factors compared between the two stocks.
Get Prestige Consumer Healthcare News Delivered to You Automatically
Sign up to receive the latest news and ratings for PBH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PBH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Prestige Consumer Healthcare Competitors List
Related Companies and Tools
